Amgen Inc. (BVMF:AMGN34)

Brazil flag Brazil · Delayed Price · Currency is BRL
64.68
-0.85 (-1.30%)
At close: Dec 4, 2025
7.60%
Market Cap 961.49B
Revenue (ttm) 191.70B
Net Income (ttm) 37.33B
Shares Out n/a
EPS (ttm) 68.93
PE Ratio 25.75
Forward PE 15.92
Dividend 1.27 (1.96%)
Ex-Dividend Date Nov 19, 2025
Volume 55
Average Volume 3,188
Open 65.20
Previous Close 65.53
Day's Range 64.68 - 65.20
52-Week Range 51.63 - 75.12
Beta 0.46
RSI 60.49
Earnings Date Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Sector Healthcare
Founded 1980
Employees 28,000
Stock Exchange Brazil Stock Exchange
Ticker Symbol AMGN34
Full Company Profile

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD Financial Statements

News

There is no news available yet.